Absci Corp Annual Report - How They Did This Year

I’ve put together this guide to help you understand Absci Corp’s performance. Instead of digging through dense filings, we’ll break down the business so you can decide if it fits your investment goals.

1. What does this company do?

Absci is a "tech-bio" firm that uses artificial intelligence to design new medicines and high-tech labs to test them. Think of them as a high-speed engine for drug discovery. They aim to create better drugs in two years for $15 million, significantly faster and cheaper than the industry standard of 4–6 years and $50 million. By combining AI with lab data, they cut out the slow "trial and error" phase of development.

2. The Big Tech Leap: Origin-1

The biggest update this year is the launch of Origin-1. This AI platform creates new antibodies from scratch.

• Why it matters: Most AI models only work on targets scientists already understand. Origin-1 can design drugs for biological sites that have never been mapped before.
• The proof: They validated this on four targets, where their AI designs matched the physical reality of the molecules during high-tech imaging. This platform is the core of their strategy to replace traditional discovery with a digital-first approach.

3. Financial performance

Absci is currently in "build mode." For 2023, the company reported $4.8 million in revenue, primarily from research partnerships. They are not yet profitable, reporting a $104.5 million loss for the year. They rely on milestone payments from partners like Merck and AstraZeneca to cover costs. These partnerships are vital because they provide cash and serve as external validation that their AI platform works.

4. Major wins: The "Clinical-Stage" Leap

Absci has officially moved into "clinical-stage" status, meaning their lead drug, ABS-201, is now being tested in humans.

• What it’s for: It treats pattern hair loss and endometriosis.
• The status: They successfully dosed the first three groups in their safety trial. They expect initial safety data in early 2026 and efficacy data in late 2026. This marks a shift from being a service provider to a drug developer with its own internal pipeline.

5. Financial health

As of late 2023, Absci held $160 million in cash and short-term investments. Based on their monthly spending of $8–$9 million, their cash runway extends into 2026. Because they spend more than they earn, the company may sell more shares to raise capital. Investors should watch this closely, as issuing more shares can reduce your ownership percentage.

6. Key risks

• Profitability: With a $100 million annual loss, the company depends on outside funding and partners to sustain operations.
• Clinical Trials: Testing drugs in humans is inherently risky. If ABS-201 fails, it could negatively impact confidence in Absci’s entire AI model.
• Competition: The AI-drug space is crowded with rivals like Recursion and Schrodinger. If competitors move faster, Absci could lose its market edge.
• Platform Dependency: The company’s value rests on its AI. If Origin-1 fails to scale or solve complex diseases, the business model faces significant challenges.

7. Future outlook

Absci is advancing five programs. Their goal is to use Origin-1 as a repeatable engine for discovery while proving their AI approach works through the success of ABS-201. Success over the next two years depends on positive clinical data and the ability to secure new, high-value partnerships.

Investor Takeaway: Absci is a high-risk, high-reward play. You are essentially betting on whether their AI can consistently outperform traditional drug discovery. If you are considering an investment, keep a close eye on their clinical trial results in 2026 and their ability to manage their cash reserves without diluting shareholders too heavily.